Compare KPTI & CNXU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | CNXU |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.8M | 208.4M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | CNXU |
|---|---|---|
| Price | $1.98 | $7.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 134.1K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,067,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $1.80 | $7.10 |
| 52 Week High | $10.99 | $13.66 |
| Indicator | KPTI | CNXU |
|---|---|---|
| Relative Strength Index (RSI) | 14.97 | 36.73 |
| Support Level | N/A | $7.62 |
| Resistance Level | $6.96 | $11.51 |
| Average True Range (ATR) | 0.74 | 1.25 |
| MACD | -0.66 | -0.08 |
| Stochastic Oscillator | 2.42 | 9.91 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings. The company focuses durable, and growing addressable markets in regenerative aesthetics, wound care, 3D-printed tissue structures, veterinary wound repair, and dental soft-tissue regeneration.